Neumirna Therapeutics
Healthcare & Life Sciences
Recent Finacing
Series A
Recent Raise
$20.7M
Neumirna Therapeutics is a biotech company developing RNA-based therapies, focusing on an Antisense Oligonucleotide treatment for drug-resistant epilepsy.
Focus Areas
RNA therapies
Antisense Oligonucleotide
drug-resistant epilepsy
clinical development
research and development
drug discovery platform
Investors
